Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tosedostat

Catalog No: tcsc0003570

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
238750-77-1

Formula:
$C_{21}H_{30}N_2O_6$

Pathway:
Metabolic Enzyme/Protease

Target:
Aminopeptidase

Purity / Grade:
>98%

Solubility:
DMSO : 25 mg/mL (61.51 mM; Need ultrasonic and warming)

Alternative Names:
CHR-2797

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
406.47

Product Description

Tosedostat is an **aminopeptidase** inhibitor.

IC50 & Target: Aminopeptidase[1]

In Vitro: Treatment of HL-60 cells with Tosedostat (CHR-2797) leads to an increase in the secretion of Stanniocalcin 2 (STC2) protein into the growth medium. Increases in *SLC7A11* expression are detectable at 60 nM Tosedostat and as early as 2 h posttreatment. The IC_{50}s for inhibition of proliferation by Tosedostat in U-937 and HuT 78 cell lines are 10 nM and >10 μM, respectively. Tosedostat treatment increases expression of amino acid deprivation response (AADR) genes in U-937 cells but not in HuT 78 cells[1]. By 24 h with 0.01 μM Tosedostat the mean MCA production is reduced to 77.8% of the untreated control cells; similarly the MCA production is reduced to 51.3% with 1 μM, 38.5% with 5 μM, and 35.3% with 10 μM Tosedostat[2].

In Vivo: Tosedostat (CHR-2797) is active as an anticancer agent *in vivo* in rodent cancer models, and a dose-response relationship has been shown in two models. The effect of Tosedostat is less apparent when the tumor burden is higher before treatment[1].